SOLO – PoC Oncology

SOLO- PoC Oncology: Specific in vitro, ex-vivo and in vivo pharmacology studies for new approaches to cancer treatment

SOLO Oncology is our solution for the growing need for preclinical pharmacological evaluation of proof of concept for innovative therapeutic approaches and products in oncology and immuno-oncology. Within the SOLO Oncology service offering, our teams of experts apply their know-how in laboratories equipped with state-of-the-art equipment.

Since 1995, we have been supporting your evaluation of therapeutic targets and the in vitro and in vivo pharmacological effects of products at different drug discovery stages.

Our in vitro & in vivo models

SOLO PoC Oncology - a large choice of modalities and specific readout for the evaluation of proof of concept in preclinical pharmacology
  • Our in vitro models

    Test your therapeutic solutions on suitable in vitro models:

    • Cancer cells (over 300 cell lines covering 90% of human cancers)
      • Cell line engineering
      • Target validation
      • Target engagement
      • Screening, combination studies
      • Proliferation (cell cycle…)
      • 2D/3D HTS, HCS
      • Clonogenic assay
      • Death (apoptosis, immunogenic…)
      • migration, invasion
    • Immune cells
      • T cell proliferation, anergy
      • PBMCs, T cells activation (IFNg, IL2 secretion, ELISPOT…)
      • DC actiavtion, phagocytosis…
      • Monocyte activation
      • Macrophage polarization
    • Tumor cells and immune cells interactions
      • Antibody dependent cell cytotoxicity
      • Antibody dependent cell phagocytosis
      • DC maturation and activation following Immunogenic cell death
      • DC antigen presentation assay
      • T cell cytotoxicity
  • Our in vivo models

    Test your therapeutic solutions on suitable in vivo models :

    • Tumor models (over 500 models covering 35 cancer pathologies)
      • Syngeneic, xenogeneic, transgenic, chemo-induced models
      • Ectopic, orthotopic, metastatic tumor growth
      • Patient-Derived Xenograft (PDX) & Cell Line-Derived Xenograft (CDX)
      • Humanized models
      • Characterized tumor growth kinetics, histology, genetics
      • Responses to standard-of-care
      • Development of new specific models on request
    • Tumor biobanking
  • Proof of concept
    • Drug efficacy
    • Drug administration (IV, IP, SC, infusion…)
    • Single agents & combination
    • Drug cancer positioning
3d illustration proteins with lymphocytes , t cells or cancer ce

Our expertise in Oncology

More than 25 years of experience in preclinical studies focusing on the characterization and qualification of the therapeutic potential of very diverse therapeutic approaches and modalities – chemical entities, peptides, oligonucleotides, biological entities, gene and cell therapies, oncolytic viruses, vaccines and others, as single agents or in combination.

SOLO Oncology is the right solution to evaluate and predict:

  • the in vitro and in vivo potential of your targets of interest,
  • the mechanisms of action
  • the efficacy of your innovative products in oncology and immuno-oncology.

Our innovative technologies at the service of your research and development programs

SOLO Oncology is based on the recognized quality and innovation introduced in our precision medicine technology modules:

  • TOT®: Qualify the potential of your molecules and targets with our tools such as phenotypic tests, organoids of human primary tumors
  • Predict® – Oncology: Select your best drug candidates with our in vitro 2D and 3D models, in vivo models of ectopic and orthotopic xenografts, syngenic, CDX, chemo-induced
  • Chi-mice®: Evaluate your new therapeutic approaches on our humanized in vivo, PDX, transgenic models
  • Pharmimage®: Monitor the effect of your treatments and define your biomarkers thanks to our multi-modal platform in translational pharmacoimaging in vivo
A large choice of specific readout to evaluate the proof of concept of your innovative therapeutic approaches in oncology and immuno-oncology